Skip to main content
Skip to section navigation
Skip to footer
Home
About
Overview
Management Team
Scientific Advisory Board
Board of Directors
Antimicrobial Resistance
Neuroinflammation
Therapeutic Solutions
Overview
Immune Therapy for Microbial Diseases
Immune Therapy for Neuroinflammation
PNAG Platform
Presentations & Publications
Pipeline
Overview
Monoclonal Antibody F598
Monoclonal Antibody AB0411
Vaccine AV0328
Vaccine AV0407
Potential of Targeting PNAG
In the News
Contact
All SEC Filings
Investors
Investors
Overview
News & Events
Overview
Press Releases
IR Calendar
Email Alerts
Company Info
Overview
Management Team
Presentations
Contacts
FAQ
Financial Info
Overview
Financial Results
Stock Data
Quote
Charts
Historical Data
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Governance
Overview
Board of Directors
Board Committees
Governance Documents
Board Diversity
Filing Type:
View All
8-A12B
DRS
FWP
S-1
S-1/A
Year:
View All
2026
2025
2024
2023
2022
Date
Form
Description
PDF
XBRL
Pages
05/02/22
S-1/A
General form of registration statement for all companies including face-amount certificate companies
Documents
expand_more
EX-23.1
194
04/20/22
S-1/A
General form of registration statement for all companies including face-amount certificate companies
Documents
expand_more
EX-3.2
EX-23.1
196
04/07/22
S-1/A
General form of registration statement for all companies including face-amount certificate companies
Documents
expand_more
EX-3.2
EX-10.1
EX-23.1
EX-99.1
236
03/07/22
S-1
General form of registration statement for all companies including face-amount certificate companies
Documents
expand_more
EX-3.1
EX-3.4
EX-10.4
EX-10.5
EX-10.6
EX-10.7
EX-23.1
EX-FILING FEES
282
01/07/22
DRS
Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
116
rss_feed
Filing RSS
Previous Page
arrow_back
Page
1
Page
2
Page
3
Email Alerts
Contacts
RSS News Feed